Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
Go back to Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.13 -0.37 (3.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.50 | 52 Week High | $9.23 | |||
| Open | $9.68 | 52 Week Low | $1.16 | |||
| Day High | $9.99 | P/E | N/A | |||
| Day Low | $9.08 | EPS | $-0.30 | |||
| Volume | 9,458,295 | |||||
